Cadila Pharma launches world’s first novel three-dose rabies vaccine ThRabis
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology
Cadila Pharma has developed a novel three-dose recombinant nano-particle-based rabies G protein vaccine. Aiming at a rabies-free India, the novel vaccine was launched by Cadila this month with the campaign ‘One, Two, Three. Rabies Free,’ a company statement said.
It also said that all the existing rabies vaccine regimens require five injections spread over 28 days to complete the full regimen. Many animal bite victims are unable to complete the full course of the vaccine due to their complicated dosing schedule, frequent visits to the hospital or clinic and potential loss of income associated with these visits. This leaves many victims unprotected and susceptible to developing rabies, which is a fatal condition.
The statement further mentioned about the ‘Cadila Against Rabies’ event held in Ahmedabad that was attended by key experts from the Association for the Prevention and Control of Rabies in India (APCRI), who spoke about the need to eradicate rabies. The panel discussion was followed by the launch of ThRabis – the world’s first novel three-dose rabies vaccine.
“With this three-dose innovative vaccine, many more lives will be saved – lives that continue to be lost to a preventable disease like rabies. This vaccine can be a game-changer in our global flight to eliminate rabies through a simpler and more convenient regimen. Continuing our journey of making affordable innovations available to the last man in society, ThRabis is one more addition to our portfolio of indigenous innovations,” Dr Rajiv Modi, CMD, Cadila Pharma, said in the statement.